aef0117
Small moleculeexperimental
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 6, 2017 (NCT03325595)
Timeline
Indications
Mechanism of action
- Cannabinoid CB1 receptorINHIBITOR
CNR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06395688 | Phase 1 | Dec 31, 2024 | Aelis Farma, National Institute on Drug Abuse (NIDA) |
| NCT05451017 | Phase 1 | Nov 30, 2022 | Aelis Farma, National Institute on Drug Abuse (NIDA) |
| NCT05554926 | Phase 1 | Nov 30, 2022 | Aelis Farma |
| NCT05322941 | Phase 2 | May 6, 2022 | Aelis Farma, Columbia University, Medical University of South Carolina, National Institute on Drug Abuse (NIDA) |
| NCT03717272 | Phase 2 | Oct 23, 2018 | Aelis Farma, ClinStar, LLC, Columbia University, National Institute on Drug Abuse (NIDA) |
| NCT03443895 | Phase 1 | Jan 8, 2018 | Aelis Farma, Biotrial, National Institute on Drug Abuse (NIDA) |
| NCT03325595 | Phase 1 | Apr 6, 2017 | Aelis Farma, Biotrial, National Institute on Drug Abuse (NIDA) |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aelis Farma | For profit | 7 | 7 | 2 | 2017 |
| National Institute on Drug Abuse (NIDA) | Government | 6 | 0 | 2 | 2017 |
| Biotrial | For profit | 2 | 0 | 1 | 2017 |
| Columbia University | Academic/Hospital | 2 | 0 | 1 | 2018 |
| ClinStar, LLC | For profit | 1 | 0 | 1 | 2018 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2022 |
6 organizations
Page 1 / 1